A special issue of Hepatoma Research
ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)
Submission deadline: 1 Jul 2021
Chronic hepatitis C virus (HCV) infection is an important cause of hepatocellular carcinoma (HCC). In the past, pegylated interferon with ribavarin was the only treatment available, which conferred limited efficacy and is contraindicated in patients with decompensated cirrhosis and other medical conditions such as autoimmune illnesses, psychiatric diseases and heart failure. The approval of direct-acting antivirals (DAAs) in recent years has led to dramatic increase in the cure rate of chronic HCV infection. Consequently, the complications arising from HCV, including HCC and decompensated cirrhosis, are expected to be declining. In this special issue, the following topics will be discussed:
• The changing epidemiology of HCV-related HCCArticles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/HR/?IssueId=592
Submission Deadline: 1 Jul 2021
Contacts: Victoria Lee, Assistant Editor, editor_Victoria@hrjournal.net